Compare CPB & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPB | LNTH |
|---|---|---|
| Founded | 1869 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.6B |
| IPO Year | 1994 | 2014 |
| Metric | CPB | LNTH |
|---|---|---|
| Price | $20.08 | $96.28 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 18 | 6 |
| Target Price | $26.06 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 6.4M | 869.7K |
| Earning Date | 06-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.63% | N/A |
| EPS Growth | ★ 6.35 | N/A |
| EPS | 1.13 | ★ 1.80 |
| Revenue | ★ $10,253,000,000.00 | $343,374,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.11 | $14.19 |
| P/E Ratio | ★ $17.98 | $51.90 |
| Revenue Growth | ★ 6.40 | 3.62 |
| 52 Week Low | $19.76 | $47.27 |
| 52 Week High | $35.00 | $98.27 |
| Indicator | CPB | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 38.01 | 69.50 |
| Support Level | $19.90 | $49.21 |
| Resistance Level | $21.46 | $98.27 |
| Average True Range (ATR) | 0.62 | 3.22 |
| MACD | 0.00 | 0.21 |
| Stochastic Oscillator | 21.19 | 86.67 |
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2025 (July year-end), snacks accounted for 43% of its revenue, followed by soup (27%), other simple meals (23%), and beverages (7%). Beyond its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and, most recently, Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.